Open AccessReduction in oral corticosteroid use in patients with severe allergic (IgE‐mediated) asthma receiving omalizumab in a real‐world setting
Author(s) -
Braunstahl GertJan,
Chlumsky Jan,
Peachey Guy,
Maykut Robert,
Chen ChienWei
Publication year - 2013
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-3-s1-p13
Subject(s) - omalizumab , medicine , asthma , immunoglobulin e , corticosteroid , allergy , maintenance therapy , dosing , pediatrics , intensive care medicine , immunology , antibody , chemotherapy
Background Patients with severe allergic asthma (SAA) are often inadequately controlled despite available treatments including high-dose inhaled corticosteroids and longacting b2-agonists. Use of oral corticosteroids (OCS) in SAA patients may not achieve full asthma control, and leads to significant long-term side effects. Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody approved in the European Union as an add-on therapy for patients with SAA. In clinical studies, omalizumab has been shown to reduce OCS use. Here we report the effect of omalizumab treatment on OCS maintenance use for up to 24 months in patients with SAA in the real-world eXpeRience registry.